Clinical Trial Search

Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.156; 0.128 proportion of participants

Primary: FEV1 Peak(0-3h) Change From Baseline — 0.252; 0.287; 0.391 Litres — p=0.2724

Primary: To Compare 2-year Overall Survival of Patients With Lymphoma Undergoing RIC SCT Between Those Receiving Tacrolimus/Sirolimus/Methotrexate and Those Receiving…

Primary: Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes — 5.55; -3.26 Incontinence Episodes

Primary: Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat — 1.4; 1.8; 1.9; 1.9 l/min/m2 — p=0.09

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 3; 26; 0; 5 participants

Primary: AUSCAN Pain Change at 4 Weeks From Baseline — -9.0; -2.2 units on a scale — p=0.014

Primary: Durable Response Rate — 2.1; 16.3 percentage of participants — p=<0.0001

Primary: Change From Baseline in HbA1c at 26 Weeks — -1.48; -1.22; -0.92 percentage of HbA1c — p=<0.001

Primary: Change From Baseline to End of Treatment in Total International Prostate Symptom Score — -5.4; -6.2; -7.0; -6.5 units on a scale — p=0.001

Primary: Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 75; 71.8; 71.7; 73.3 Percentage of participants

Primary: Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year — 13.3; 9.7; 11.2 units on a scale — p=<0.001

Primary: Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm — 29; 7 participants

Primary: Change From Baseline in Mean Number of Nocturnal Voids — -1.12; -1.30; -1.42; -1.47 nocturnal voids

Primary: Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] — -1.579; -1.110 units on a scale